Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.

Manon Réda,Anaïs Fouquier,Isabelle Desmoulins,Didier Mayeur,Courèche Kaderbhai,Silvia Ilie,Audrey Hennequin,Bruno Coudert,Aurélie Bertaut,Sylvain Ladoire

Breast (Edinburgh, Scotland)（2023）

引用 0|浏览9

暂无评分

摘要

Although only a minority of MBC patients are concerned, taxane rechallenge appears to be a pragmatic option with an acceptable tolerance, and good efficacy, especially when these drugs have shown clinical activity earlier in the disease course, and/or have been stopped for reasons other than progression.

查看译文

关键词

Breast cancer,Chemotherapy,Docetaxel,Metastatic cancer,Paclitaxel,Rechallenge,Taxanes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要